New Drug Controls Sickle Cell Disease-Linked Hypertension
University of Maryland School of Medicine
Treatment for lung condition could help patients with SCD control complications from hypertension and kidney damage
The CREDENCE trial demonstrated how canagliflozin treatment brought down the levels of cardiorenal blood biomarkers
ADLM guidance shares tools and strategies to achieve bias-free patient care